Metabolomics and ischaemic heart disease

Area of Science:

• Cardiovascular Research
• Metabolomics
• Lipidomics

Background:

• Ischaemic heart disease (IHD) is a major global health burden, with complex causes including dyslipidaemia, oxidative stress, and inflammation.
• Despite advances, residual risk and high prevalence necessitate improved early detection, prevention, and therapeutic strategies for cardiovascular events.

Purpose of the Study:

• To review evidence from metabolomic and lipidomic studies on ischaemic heart disease.
• To explore the role of plasma lipid profiling in assessing IHD risk and therapeutic responses.
• To highlight the potential of omics disciplines in understanding, detecting, and treating IHD.

Main Methods:

• Review of studies utilizing metabolomics and lipidomics in the context of ischaemic heart disease.
• Analysis of data generated by advanced technologies like magnetic resonance and mass spectrometry.
• Application of specific statistical and bioinformatics tools for data interpretation.

Main Results:

• Metabolomics and lipidomics have shown utility in population profiling, biomarker identification, and monitoring therapeutic responses in IHD.
• The plasma lipidome demonstrates predictive and re-classification capacity for individuals at various risk levels for cardiovascular events.
• These fields offer insights into the mechanisms underlying IHD.

Conclusions:

• Metabolomic and lipidomic approaches provide valuable tools for advancing the understanding and management of ischaemic heart disease.
• Plasma lipid profiling holds significant potential for assessing cardiovascular risk and guiding treatment.
• Integration of omics disciplines is crucial for future progress in IHD detection and therapy.